Published in Cells on December 21, 2016
Novel therapeutic approaches: Rett syndrome and human induced pluripotent stem cell technology. Stem Cell Investig (2017) 0.75
Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell (2006) 120.51
Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell (2007) 101.42
Induced pluripotent stem cell lines derived from human somatic cells. Science (2007) 71.50
Reprogramming of human somatic cells to pluripotency with defined factors. Nature (2007) 30.84
Disease-specific induced pluripotent stem cells. Cell (2008) 16.95
Generation of human induced pluripotent stem cells from dermal fibroblasts. Proc Natl Acad Sci U S A (2008) 13.09
Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat Biotechnol (2009) 12.40
Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature (2008) 12.21
Generation of pluripotent stem cells from adult mouse liver and stomach cells. Science (2008) 10.55
A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell (2010) 7.51
Drug-induced hepatotoxicity. N Engl J Med (2003) 7.11
Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res (2009) 7.09
Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature (2009) 7.04
How were new medicines discovered? Nat Rev Drug Discov (2011) 7.00
Clinical development success rates for investigational drugs. Nat Biotechnol (2014) 5.32
Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. Hepatology (2012) 3.94
Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J Clin Invest (2010) 3.91
Technical challenges in using human induced pluripotent stem cells to model disease. Cell Stem Cell (2009) 3.42
Targeted gene correction of laminopathy-associated LMNA mutations in patient-specific iPSCs. Cell Stem Cell (2011) 3.32
Microfluidic organs-on-chips. Nat Biotechnol (2014) 3.29
Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov (2005) 3.23
Differential responses to lithium in hyperexcitable neurons from patients with bipolar disorder. Nature (2015) 3.21
Directing human embryonic stem cell differentiation towards a renal lineage generates a self-organizing kidney. Nat Cell Biol (2013) 3.07
Kidney organoids from human iPS cells contain multiple lineages and model human nephrogenesis. Nature (2015) 2.95
Efficient generation of hepatocyte-like cells from human induced pluripotent stem cells. Cell Res (2009) 2.74
Next-generation biomarkers for detecting kidney toxicity. Nat Biotechnol (2010) 2.64
Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Circulation (2013) 2.57
Isolation of hepatoblasts based on the expression of Dlk/Pref-1. J Cell Sci (2003) 2.38
Deconstructing the drug development process: the new face of innovation. Clin Pharmacol Ther (2010) 2.38
Assessment of emerging biomarkers of liver injury in human subjects. Toxicol Sci (2013) 2.34
Human iPSC-based modeling of late-onset disease via progerin-induced aging. Cell Stem Cell (2013) 2.31
Pluripotent stem cell lines. Genes Dev (2008) 2.25
Redefining the in vivo origin of metanephric nephron progenitors enables generation of complex kidney structures from pluripotent stem cells. Cell Stem Cell (2013) 2.20
iPS cells: a game changer for future medicine. EMBO J (2014) 2.15
Generation of insulin-secreting islet-like clusters from human skin fibroblasts. J Biol Chem (2008) 2.04
Characterization of human induced pluripotent stem cell-derived retinal pigment epithelium cell sheets aiming for clinical application. Stem Cell Reports (2014) 2.03
What are biomarkers? Curr Opin HIV AIDS (2010) 1.80
Induced pluripotent stem cell-derived hepatocytes have the functional and proliferative capabilities needed for liver regeneration in mice. J Clin Invest (2010) 1.66
Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nat Rev Drug Discov (2011) 1.65
Human embryonic stem cells: research, ethics and policy. Hum Reprod (2003) 1.50
Stem cells: hype or hope? Drug Discov Today (2002) 1.48
Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut (2014) 1.46
iPSC technology: platform for drug discovery. Point. Clin Pharmacol Ther (2011) 1.45
Small molecules induce efficient differentiation into insulin-producing cells from human induced pluripotent stem cells. Stem Cell Res (2011) 1.45
Biomarker method validation in anticancer drug development. Br J Pharmacol (2007) 1.41
The determination and interpretation of the therapeutic index in drug development. Nat Rev Drug Discov (2012) 1.40
Genetic Variability Overrides the Impact of Parental Cell Type and Determines iPSC Differentiation Potential. Stem Cell Reports (2016) 1.38
Genetic and epigenetic stability of human pluripotent stem cells. Nat Rev Genet (2012) 1.38
Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol (2012) 1.31
Opportunities for use of human iPS cells in predictive toxicology. Clin Pharmacol Ther (2011) 1.28
Biomarkers and surrogate endpoints. Br J Clin Pharmacol (2005) 1.25
Three-dimensional culture and cAMP signaling promote the maturation of human pluripotent stem cell-derived hepatocytes. Development (2013) 1.23
Nephron organoids derived from human pluripotent stem cells model kidney development and injury. Nat Biotechnol (2015) 1.21
3D spheroid culture of hESC/hiPSC-derived hepatocyte-like cells for drug toxicity testing. Biomaterials (2012) 1.19
Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies. Drug Metab Dispos (2008) 1.14
Intrinsic versus idiosyncratic drug-induced hepatotoxicity--two villains or one? J Pharmacol Exp Ther (2009) 1.14
Allele-biased expression in differentiating human neurons: implications for neuropsychiatric disorders. PLoS One (2012) 1.13
Embryonic stem cells in drug discovery. Nat Rev Drug Discov (2004) 1.12
Generation of a vascularized and functional human liver from an iPSC-derived organ bud transplant. Nat Protoc (2014) 1.10
Trends in clinical success rates. Nat Rev Drug Discov (2016) 1.07
Assessing iPSC reprogramming methods for their suitability in translational medicine. J Cell Biochem (2012) 1.07
HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans. Drug Metab Dispos (2007) 1.03
Modeling chemotherapeutic neurotoxicity with human induced pluripotent stem cell-derived neuronal cells. PLoS One (2015) 1.02
Induced pluripotent stem cells from CINCA syndrome patients as a model for dissecting somatic mosaicism and drug discovery. Blood (2012) 1.01
Assessing the translatability of drug projects: what needs to be scored to predict success? Nat Rev Drug Discov (2009) 1.01
Efficient Detection and Purification of Cell Populations Using Synthetic MicroRNA Switches. Cell Stem Cell (2015) 1.00
Banking human induced pluripotent stem cells: lessons learned from embryonic stem cells? Cell Stem Cell (2013) 1.00
A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity. Circ Res (2011) 0.98
Survival of human induced pluripotent stem cell-derived midbrain dopaminergic neurons in the brain of a primate model of Parkinson's disease. J Parkinsons Dis (2011) 0.98
Biomarkers for drug-induced renal damage and nephrotoxicity-an overview for applied toxicology. AAPS J (2011) 0.98
Human-on-chip for therapy development and fundamental science. Curr Opin Biotechnol (2013) 0.97
Development of Sendai virus vectors and their potential applications in gene therapy and regenerative medicine. Curr Gene Ther (2012) 0.97
In vitro developmental neurotoxicity (DNT) testing: relevant models and endpoints. Neurotoxicology (2009) 0.96
Drug-induced nephrotoxicity: clinical impact and preclinical in vitro models. Mol Pharm (2014) 0.95
Induced pluripotent stem cells: a new technology to study human diseases. Int J Biochem Cell Biol (2011) 0.95
Quantitative proteomic analysis of induced pluripotent stem cells derived from a human Huntington's disease patient. Biochem J (2012) 0.93
Prediction of Drug-Induced Liver Injury in Micropatterned Co-cultures Containing iPSC-Derived Human Hepatocytes. Toxicol Sci (2015) 0.92
A human liver microphysiology platform for investigating physiology, drug safety, and disease models. Exp Biol Med (Maywood) (2015) 0.91
Kidney-on-a-Chip Technology for Drug-Induced Nephrotoxicity Screening. Trends Biotechnol (2015) 0.90
Cell- and biomarker-based assays for predicting nephrotoxicity. Expert Opin Drug Metab Toxicol (2014) 0.90
Translatability scoring in drug development: eight case studies. J Transl Med (2012) 0.89
Requirements for a lead compound to become a clinical candidate. BMC Neurosci (2008) 0.89
Organoid-on-a-chip and body-on-a-chip systems for drug screening and disease modeling. Drug Discov Today (2016) 0.89
Biomarkers of therapeutic response in multiple sclerosis: current status. Mol Diagn Ther (2014) 0.87
Nephron reconstitution from pluripotent stem cells. Kidney Int (2014) 0.87
Reprogramming barriers and enhancers: strategies to enhance the efficiency and kinetics of induced pluripotency. Cell Regen (Lond) (2015) 0.87
Urinary kidney biomarkers for early detection of nephrotoxicity in clinical drug development. Br J Clin Pharmacol (2014) 0.87
Concise Review: Patient-Derived Stem Cell Research for Monogenic Disorders. Stem Cells (2015) 0.87
Screening technologies for small molecule discovery: the state of the art. Chem Biol (2014) 0.86
Evaluation of biomarkers for in vitro prediction of drug-induced nephrotoxicity: comparison of HK-2, immortalized human proximal tubule epithelial, and primary cultures of human proximal tubular cells. Pharmacol Res Perspect (2015) 0.86
Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment. Arch Toxicol (2015) 0.86
KCC2 rescues functional deficits in human neurons derived from patients with Rett syndrome. Proc Natl Acad Sci U S A (2016) 0.86
High-Throughput Screening Using iPSC-Derived Neuronal Progenitors to Identify Compounds Counteracting Epigenetic Gene Silencing in Fragile X Syndrome. J Biomol Screen (2015) 0.85
A Precision Medicine Approach to the Rescue of Function on Malignant Calmodulinopathic Long QT Syndrome. Circ Res (2016) 0.85
Human Brain Microvascular Endothelial Cells Derived from the BC1 iPS Cell Line Exhibit a Blood-Brain Barrier Phenotype. PLoS One (2016) 0.85
Extending kinome coverage by analysis of kinase inhibitor broad profiling data. Drug Discov Today (2015) 0.85
Translation of Human-Induced Pluripotent Stem Cells: From Clinical Trial in a Dish to Precision Medicine. J Am Coll Cardiol (2016) 0.85
Statistics without tears: Populations and samples. Ind Psychiatry J (2010) 0.84
Human induced pluripotent stem cell-derived hepatocytes for toxicology testing. Expert Opin Drug Metab Toxicol (2014) 0.84
Relevance of in vitro neurotoxicity testing for regulatory requirements: challenges to be considered. Neurotoxicol Teratol (2008) 0.83